Behavioral Health News

Resting State Functional Connectivity in Women With Depression Following Pregnenolone Administration

By Journal of Clinical Psychiatry 2 min read

Original Source: Journal of Clinical Psychiatry, all rights reserved. —

Background: Neurosteroids, such as pregnenolone, have potential in mood disorder treatment. Because depression is associated with dysregulated connectivity in brain networks, a systems-level biomarker for neurosteroids modulation of large-scale brain networks can offer critical insight into circuits underlying treatment response. To our knowledge, no studies have examined resting-state functional connectivity (rsFC) in people with depression following pregnenolone administration.

Methods: In this crossover design study conducted between 2019–2021, women (n=29, mean age=45.6 years) with major depressive disorder (DSM-5) were randomized to 7 days of oral pregnenolone 500 mg/d, pregnenolone 800 mg/d, and placebo with a 14-day washout between conditions. After each treatment, steroid levels and resting-state fMRI (rsfMRI) data were collected. A seed-based voxel-wise analysis, with bilateral amygdala as seed, investigated rsFC alterations following treatment conditions in a per-protocol sample (n=11).

Results: Compared to placebo, pregnenolone 500 mg/d was associated with decreased connectivity between the bilateral amygdala and left frontal pole (PFDR=.011). Difference in amygdala connectivity between pregnenolone 800 mg/d and placebo was nonsignificant. Allopregnanolone serum levels increased significantly with administration of either pregnenolone dose as compared to placebo.

Conclusions: Findings suggest that pregnenolone 500 mg/d was associated with decreased connectivity between the amygdala and frontal pole, brain regions pertinent to depression and cognitive control. Presence of rsFC changes at 500 mg/d but not 800 mg/d suggests an inverted-U dose–response pattern, where moderate dosing optimally engages neural circuits compared to higher doses.

Trial Registration: ClinicalTrials.gov identifier: NCT03645096 J Clin Psychiatry 2026;87(4):26m16360 Author affiliations are listed at the end of this article.

Read the full article at Psychiatrist.com

Journal of Clinical Psychiatry, all rights reserved.

Share this post

Integrated Psychiatric Consultants

Office Hours:
Mon-Fri, 9 a.m. - 5 p.m. CT

Reach out today.

Integrated Psychiatric Consultants (IPC) is committed to protecting and respecting your privacy. Our team will use the information collected here solely to serve your needs and notify you about relevant services. To consent, please check the box above and submit this form.

Please note, this consent applies to all forms of communications, including SMS. If you have provided a mobile phone number above, you agree to receiving SMS messages from IPC. You may unsubscribe at any time. Message frequency varies. Messaging and data rates may apply. Reply STOP to cancel. For more information, please review our Privacy Policy.